Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration
- PMID: 20106824
- DOI: 10.1093/ndt/gfp776
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration
Abstract
Background: Residual proteinuria is a strong modifiable risk factor for renal failure progression. We previously showed that the antiproteinuric effect of combined half doses of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) is increased by raising diuretic dosage. Methods. We tested whether uptitration of loop diuretics on top of combined half doses of ACEI and ARB would better decrease proteinuria than uptitration to combined full doses of ACEI and ARB in a randomized, crossover, three periods of 6-week controlled study. Eighteen patients with stable proteinuria over 1 g/day with combined ramipril at 5 mg/day and valsartan at 80 mg/day in addition to conventional antihypertensive treatments were randomized to receive combined ramipril at 5 mg/day and valsartan at 80 mg/day, or combined ramipril at 10 mg/day and valsartan at 160 mg/day, or combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage in random order. The primary end point was the mean urinary protein/creatinine ratio in two 24-hour urine collections at the end of the three treatment periods. Secondary end points included mean 24-hour proteinuria, home systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP) and estimated glomerular filtration rate (eGFR) levels.
Results: The geometric mean urinary protein/creatinine ratio was lower with combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage compared to combined ramipril at 5 mg/day and valsartan at 80 mg/day, but also to combined ramipril at 10 mg/day and valsartan at 160 mg/day. These differences remained significant after adjustment for SBP, DBP or MAP and 24-hour natriuresis but not after adjustment on eGFR. Diuretic dosage uptitration did not increase the number of home systolic blood pressure measurements below 100 mmHg, but led to a statistically significant increase in the number of symptomatic hypotension episodes.
Conclusions: A cautious uptitration of loop diuretic dosage in addition to combined half doses of ACEI and ARB better decrease proteinuria in patients with CKD and high residual proteinuria than uptitration to full dose of combined ACEI and ARB. This antiproteinuric effect of diuretics was partly explained by an eGFR decrease, suggesting the contribution of haemodynamic modifications, whose safety on the long term still need to be addressed.
Comment in
-
"Proteinuria" itself cannot be taken as a definite marker of improved renal function.Nephrol Dial Transplant. 2010 Nov;25(11):3799; author reply 3799-800. doi: 10.1093/ndt/gfq508. Epub 2010 Aug 23. Nephrol Dial Transplant. 2010. PMID: 20732923 No abstract available.
Similar articles
-
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.J Am Soc Nephrol. 2005 Feb;16(2):474-81. doi: 10.1681/ASN.2004060505. Epub 2004 Dec 22. J Am Soc Nephrol. 2005. PMID: 15615822 Clinical Trial.
-
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5. Circulation. 2009. PMID: 19805651 Clinical Trial.
-
Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.Hypertens Res. 2010 Nov;33(11):1150-4. doi: 10.1038/hr.2010.145. Epub 2010 Aug 12. Hypertens Res. 2010. PMID: 20703230 Clinical Trial.
-
Treatment of hypertension in chronic kidney disease.Semin Nephrol. 2005 Nov;25(6):435-9. doi: 10.1016/j.semnephrol.2005.05.016. Semin Nephrol. 2005. PMID: 16298269 Review.
-
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.
Cited by
-
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.Int J Mol Sci. 2022 Sep 17;23(18):10882. doi: 10.3390/ijms231810882. Int J Mol Sci. 2022. PMID: 36142794 Free PMC article. Review.
-
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3. Cochrane Database Syst Rev. 2023. PMID: 37466151 Free PMC article.
-
Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth?Diabetes Care. 2022 Oct 1;45(10):e148-e149. doi: 10.2337/dc22-0921. Diabetes Care. 2022. PMID: 35973076 Free PMC article. No abstract available.
-
Reduction of mean arterial pressure and proteinuria by the effect of ACEIs (Lisinopril) in Kurdish hypertensive patients in Hawler City.Glob J Health Sci. 2012 Jun 30;4(5):14-9. doi: 10.5539/gjhs.v4n5p14. Glob J Health Sci. 2012. PMID: 22980373 Free PMC article. Clinical Trial.
-
The kidney in type 2 diabetes therapy.Rev Diabet Stud. 2011 Fall;8(3):392-402. doi: 10.1900/RDS.2011.8.392. Epub 2011 Nov 10. Rev Diabet Stud. 2011. PMID: 22262076 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous